| Not Yet Recruiting | Effect of a Preoperative Sensory Modulation Room on Pain, Anxiety, and Sleep in Kidney Transplant Patients NCT07533669 | Sakarya University | N/A |
| Recruiting | Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study NCT07045467 | Qianfoshan Hospital | Phase 1 |
| Recruiting | The Effect of Emotion-Focused Intervention on Emotion Regulation and Well-Being of Individuals With Transplant NCT07294183 | Akdeniz University | N/A |
| Recruiting | Evaluation of the Efficacy of Dd-cfDNA in Routine Patient Care in Kidney Transplant Recipients" NCT06406179 | Assistance Publique - Hôpitaux de Paris | N/A |
| Not Yet Recruiting | Optimal Dose of Anti-lymphocyte Globulin in Kidney Transplant Recipients With Low Immunological Risk NCT06744400 | Centre Hospitalier Universitaire de Besancon | Phase 1 |
| Not Yet Recruiting | Effect of Probiotics on Immunosuppressive-drug-associated Diarrhea Among Renal Transplant Recipients NCT06150287 | State University of New York - Upstate Medical University | EARLY_Phase 1 |
| Not Yet Recruiting | Dexmedetomidine and Kidney Transplantation NCT05935293 | Eduardo Schiffer | Phase 4 |
| Recruiting | Knowledge of Cardiovascular Risk Factors in Chronic Kidney Disease Patients NCT06674031 | Hacettepe University | — |
| Recruiting | Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients NCT06026592 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Exercise Capacity in Kidney Transplant Recipients NCT06706154 | Hacettepe University | — |
| Not Yet Recruiting | Flumazenil Antagonism of Remimazolam in Kidney Transplant Patients NCT06531369 | Qianfoshan Hospital | Phase 1 |
| Recruiting | Muscle Oxygenation, Functional Capacity and Frailty in Kidney Transplant Recipients with and Without Inspirato NCT06706492 | Hacettepe University | — |
| Active Not Recruiting | A Study of TCD601 in de Novo Renal Transplant Recipients NCT05669001 | ITB-Med LLC | Phase 2 |
| Completed | Whole Body Vibration Versus Aerobic Training on Interleukin 6 and Endurance After Renal Transplantation NCT07333105 | Cairo University | N/A |
| Suspended | Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transpla NCT04844814 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Quantify the Benefits of Biomarkers in Routine Patient Care in Kidney Transplant Recipients NCT04774575 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx) NCT05208788 | University Hospital Tuebingen | — |
| Completed | Erector Spinae Plane Block in Renal Transplantation Donors NCT04863716 | Koc University Hospital | N/A |
| Withdrawn | Acthar for Treatment of Post-transplant FSGS NCT02399462 | University of North Carolina, Chapel Hill | Phase 4 |
| Completed | Effects of Reflexology in Transplant Patients NCT05833750 | Sanko University | N/A |
| Completed | HErnias REparation After Kidney Transplantation Study NCT04730492 | University Hospital, Montpellier | — |
| Unknown | Prostate Cancer in Renal Transplants Recipients NCT04642833 | University of Florence | — |
| Unknown | The Safety and Efficacy of Micro-energy Ultrasound in the Treatment of Renal Insufficiency After Renal Transpl NCT04119427 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy NCT04052867 | University of Malaya | N/A |
| Unknown | Comparison Thymoglobulin® and Grafalon® NCT03996278 | University Hospital, Brest | — |
| Completed | The POWERED Study: Prophylaxis With Metformin to Prevent PTDM NCT05240274 | Barts & The London NHS Trust | Phase 2 |
| Active Not Recruiting | Envarsus XR® in Adolescent Renal Transplant Recipients NCT03266393 | University of California, Los Angeles | Phase 4 |
| Active Not Recruiting | Impact of the Use of Remote Monitoring in the Follow-up of the Renal Transplant Patient. NCT03750331 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Terminated | Pneumococcal Conjugate Vaccine in Aging Renal Transplant NCT03802994 | VA Office of Research and Development | EARLY_Phase 1 |
| Completed | Tolerance by Engaging Antigen During Cellular Homeostasis NCT03504241 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody- NCT03098238 | University Hospital, Montpellier | N/A |
| Unknown | Outcome of Living Donor Renal Transplantation in Assiut Urology and Nephrology University Hospital ,Initial Ex NCT03338140 | Assiut University | — |
| Completed | Metabolomics in Assessing the Quality of Kidney Transplants Retained on a LifePort® Perfusion Machine NCT03024229 | University Hospital, Tours | N/A |
| Completed | Effect of Genetic Polymorphism on Calcineurin Inhibitors Levels in Egyptian Renal Transplant Patients NCT03830255 | Helwan University | — |
| Active Not Recruiting | Mesenchymal Stromal Cells in Living Donor Kidney Transplantation NCT03478215 | The Methodist Hospital Research Institute | Phase 2 |
| Unknown | Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients NCT03114826 | Centre Hospitalier Universitaire, Amiens | — |
| Recruiting | Combined Kidney and Hematopoietic Stem Cell Transplantation for Tolerance Induction NCT05086003 | Rabin Medical Center | Phase 2 |
| Completed | A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by P NCT02564497 | Bristol-Myers Squibb | Phase 1 |
| Completed | A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective M NCT02587052 | Vastra Gotaland Region | — |
| Completed | 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation NCT02444429 | Hospices Civils de Lyon | Phase 3 |
| Completed | Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. NCT02238418 | Hospices Civils de Lyon | Phase 4 |
| Completed | A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Onc NCT02147938 | Astellas Pharma S.A.S. | — |
| Unknown | Contribution of Diffusion MRI in Renal Graft Transplantation NCT02803684 | CHU de Reims | N/A |
| Unknown | The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients NCT02113774 | Rabin Medical Center | Phase 4 |
| Completed | Computer Guided Doing of Tacrolimus in Renal Transplantation NCT02010320 | University of Oslo School of Pharmacy | Phase 4 |
| Completed | Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) NCT01950819 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx) NCT02020642 | Centre Hospitalier Universitaire Vaudois | N/A |
| Completed | Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation NCT01899456 | Technical University of Munich | N/A |
| Completed | A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Rena NCT01822483 | Irmandade Santa Casa de Misericórdia de Porto Alegre | Phase 4 |
| Completed | Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure NCT01817504 | Hospices Civils de Lyon | N/A |
| Withdrawn | Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation NCT01586845 | Aurinia Pharmaceuticals Inc. | Phase 3 |
| Completed | Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation NCT01753973 | University of Sao Paulo General Hospital | — |
| Completed | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients NCT01843348 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Belatacept Early Steroid Withdrawal Trial NCT01729494 | University of Cincinnati | Phase 4 |
| Completed | Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsio NCT01596062 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Hepatitis C in Renal Transplant Recipients NCT02108301 | Prof. Dr. Alice Schmidt | Phase 4 |
| Completed | AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation NCT01435291 | Centre Hospitalier Universitaire de Nice | Phase 4 |
| Terminated | Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation NCT01436305 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | CE-US in Renal Transplantation NCT01815320 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modif NCT01742676 | Astellas Pharma Korea, Inc. | Phase 4 |
| Unknown | Clonal Deletion on Living-Relative Donor Kidney Transplantation NCT01408797 | Fuzhou General Hospital | Phase 1 / Phase 2 |
| Completed | The Impact of Magnesium Supplementation on Insulin Resistance and Secretion in Renal Transplant Recipients NCT01291030 | University Hospital, Ghent | N/A |
| Completed | Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients NCT01236378 | Pfizer | Phase 1 |
| Terminated | Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation NCT01276834 | Dianet Dialysis Centers | Phase 4 |
| Completed | Catalytic Antibodies to Predict Uninvasively Late Transplant Failure NCT02843295 | Hospices Civils de Lyon | N/A |
| Withdrawn | Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation NCT01149993 | Georgetown University | Phase 4 |
| Unknown | Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Reci NCT01068067 | Sun Yat-sen University | N/A |
| Completed | Behavioral Contract Adherence Intervention NCT01739803 | University of Tennessee | N/A |
| Completed | Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenol NCT01064791 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodru NCT00978965 | Medical University of Vienna | — |
| Unknown | Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis NCT01001065 | University of Zurich | — |
| Completed | Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation NCT00935298 | The Second Artillery General Hospital | Phase 4 |
| Terminated | Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients P NCT00956293 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Reduced 11-b-HSD Activity, a Novel Mechanism of Salt Sensitivity and Hypertension After Renal Allograft Dona NCT01009229 | Insel Gruppe AG, University Hospital Bern | N/A |
| Completed | Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal o NCT01023815 | Novartis | Phase 3 |
| Unknown | Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation NCT00903188 | University Hospital, Antwerp | Phase 4 |
| Completed | Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thy NCT00842699 | Brigham and Women's Hospital | — |
| Completed | Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment NCT00714480 | Swedish Medical Center | N/A |
| Completed | Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD) NCT00697112 | Pfizer | — |
| Completed | Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation NCT00656695 | Imam Khomeini Hospital | Phase 4 |
| Terminated | A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) i NCT00658333 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Belatacept Pharmacokinetic Trial in Renal Transplantation NCT00578448 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation NCT00568477 | Technical University of Munich | Phase 2 |
| Completed | Interaction Between Rimonabant and Cyclosporine and Tacrolimus NCT00525681 | University of Oslo School of Pharmacy | Phase 4 |
| Unknown | Interstitial Lung Abnormalities in Renal Transplant Recipients NCT01017757 | University of Parma | — |
| Completed | Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfo NCT00713284 | California Pacific Medical Center Research Institute | Phase 4 |
| Completed | Gene Polymorphisms in Tacrolimus Drug Interactions NCT00620841 | KU Leuven | — |
| Completed | Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without St NCT00413920 | Novartis | Phase 3 |
| Completed | The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates NCT00693576 | Shiraz University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Renal Transplantation With Immune Monitoring NCT00419575 | Washington University School of Medicine | — |
| Completed | Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combinat NCT00425308 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With NCT00400400 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticoster NCT00369278 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Renal Transplantation and Inhaled Anesthetic Sevoflurane (SEVOREIN) NCT00337051 | University Hospital, Bordeaux | Phase 3 |
| Completed | A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolim NCT00369161 | Novartis | Phase 4 |
| Terminated | Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation NCT00579592 | University of Wisconsin, Madison | N/A |
| Completed | Safety and Efficacy Study of Rituximab in Renal Transplantation NCT00255593 | Karolinska University Hospital | Phase 1 |
| Terminated | Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients. NCT00332839 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemu NCT00154310 | Novartis | Phase 4 |
| Completed | Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients NCT00154297 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recip NCT00204321 | University Hospital Muenster | Phase 4 |
| Completed | Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Follo NCT00139009 | University of Oslo School of Pharmacy | Phase 4 |
| Completed | Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients NCT00239876 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Re NCT00223028 | University Hospital Schleswig-Holstein | Phase 4 |
| Completed | Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Re NCT00149968 | Novartis | Phase 4 |
| Unknown | Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant NCT00994305 | University of Sao Paulo General Hospital | N/A |
| Unknown | Induction of Donor-Specific Tolerance in Renal Allograft Recipients (Living Donor) With TAIZ-Monocytes NCT00223067 | University Hospital Schleswig-Holstein | Phase 1 |
| Completed | Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant NCT00114777 | Bristol-Myers Squibb | Phase 3 |
| Completed | Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients NCT00170820 | Novartis Pharmaceuticals | Phase 4 |
| Completed | ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal NCT00170846 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients NCT00238953 | Novartis | Phase 4 |
| Completed | A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhib NCT00214266 | University of Wisconsin, Madison | Phase 2 |
| Completed | Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus NCT02686619 | Hoffmann-La Roche | Phase 3 |
| Completed | Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients NCT00239798 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI I NCT00150020 | Novartis | Phase 4 |
| Completed | Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitor NCT00154232 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Investigation of the Steady State Pharmacokinetics of Tacrolimus, Mycophenolate Mofetil and Fluvastatin After NCT00223015 | University Hospital Schleswig-Holstein | Phase 4 |
| Completed | Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplan NCT00239863 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study of Tolerant Kidney Transplant Recipients NCT01338779 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients NCT00239811 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Correction of Anaemia and Progression of Renal Failure on Transplanted Patients NCT00396435 | Centre Hospitalier Universitaire, Amiens | Phase 4 |
| Completed | Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation NCT00141037 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric NCT00240955 | Novartis | Phase 4 |
| Unknown | TAIZ -Monocytes for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney) NCT00223093 | University Hospital Schleswig-Holstein | Phase 1 |
| Completed | Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclospor NCT00443937 | Charite University, Berlin, Germany | Phase 4 |
| Completed | Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal NCT00170833 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study to Evaluate FK778 in Kidney Transplant Patients NCT00189735 | Astellas Pharma Inc | Phase 2 |
| Completed | Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients NCT00776750 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Completed | A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Reje NCT00089947 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant NCT00063817 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Fibrin Sealant in Renal Transplantation NCT00910052 | Hennepin County Medical Center, Minneapolis | N/A |
| Completed | Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipie NCT00239070 | Novartis | Phase 3 |
| Completed | Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients NCT00239785 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Cranoc Lipid Study in Renal Transplantation NCT00223041 | University Hospital Schleswig-Holstein | Phase 2 / Phase 3 |
| Completed | Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclospor NCT00238940 | Novartis | Phase 3 |
| Terminated | Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant NCT00148252 | University of Oslo School of Pharmacy | Phase 4 |
| Completed | A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receiv NCT00238979 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Optimizing Prograf® Therapy in Renal Transplant Patients NCT00297765 | Astellas Pharma Inc | Phase 4 |
| Completed | Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant R NCT00238966 | Novartis | Phase 4 |
| Completed | Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation NCT00685061 | University of Miami | Phase 4 |
| Completed | Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipie NCT00241059 | Novartis | Phase 4 |
| Completed | Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients NCT00239902 | Novartis Pharmaceuticals | Phase 2 |
| Completed | MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal NCT00214279 | University of Wisconsin, Madison | N/A |
| Completed | Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recip NCT00038948 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| Completed | This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001 NCT00531440 | Novartis Pharmaceuticals | Phase 3 |
| Completed | This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different NCT00531063 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients NCT00176059 | University of Giessen | EARLY_Phase 1 |
| Completed | Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk NCT00682292 | University Hospital, Lille | Phase 3 |
| Terminated | Study Evaluating Rapamune in Patients After Kidney Transplantation NCT00240214 | Wyeth is now a wholly owned subsidiary of Pfizer | — |
| Completed | Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplante NCT00035555 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Tra NCT00200551 | Nantes University Hospital | Phase 4 |
| Completed | Prediction of NODAT After Renal Transplantation NCT00442988 | KU Leuven | — |
| Completed | A Study to Compare Early Steroid Withdrawal and Long-Term Steroid Maintenance Therapy in Kidney Transplant Pat NCT00650468 | Astellas Pharma Inc | Phase 4 |
| Completed | Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients NCT00411944 | KU Leuven | — |
| Completed | Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chroni NCT00637143 | Astellas Pharma Inc | Phase 4 |
| Completed | Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients NCT00428064 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 |
| No Longer Available | A Belatacept Compassionate Use Study for Patients With a Kidney Transplant NCT00719225 | Bristol-Myers Squibb | — |